A 10-Q Quarterly Reports

Agilent Technologies, Inc. reported robust financial results for the period ended April 30, 2026. Total net revenue increased by 10% year-over-year for the quarter and 8% for the six-month period, driven by broad-based growth across all segments and geographic regions. Net income saw a significant increase, reaching $339 million in the quarter and $644 million year-to-date, up from $215 million and $533 million in the prior year, respectively. The company continues to execute on its strategic priorities, including investing in research and development and expanding its product and service portfolio. A notable event was the definitive agreement to acquire BC Midco I, Inc. for approximately $950 million, which is expected to close by the end of fiscal year 2026 and will be integrated into the Life Sciences and Diagnostics Markets segment. Agilent also announced its board declared a quarterly dividend of $0.255 per share. Despite global economic uncertainties, the company has effectively mitigated impacts from geopolitical tensions and tariffs through strategic initiatives.

Agilent Technologies, Inc. reported total net revenue of $1,798 million for the three months ended January 31, 2026, a 7% increase year-over-year, with favorable foreign currency movements contributing 3 percentage points to this growth. Net income for the quarter was $305 million, a slight decrease from $318 million in the prior year period. While overall revenue grew, driven by increases across all segments and geographic regions, the company faced increased costs impacting gross and operating margins. Notably, higher tariffs, unfavorable business mix including the specialty CDMO business, wage increases, and restructuring costs contributed to a decrease in gross margin. Selling, general, and administrative expenses also saw a significant increase, partly due to transformation initiatives and restructuring costs. Despite these pressures, the company continues to invest in R&D and capacity expansion, particularly for nucleic acid-based therapeutics.

Agilent Technologies, Inc. reported solid revenue growth for the third quarter and the first nine months of fiscal year 2025, with total net revenue increasing by 10% and 6% year-over-year, respectively. This growth was driven by strong performance across all segments, particularly Life Sciences and Diagnostics Markets, which saw a 14% increase in Q3 revenue, aided by the BIOVECTRA acquisition. Despite revenue growth, net income for the nine-month period decreased compared to the prior year, largely due to higher costs, including increased tariffs and shipping expenses, and unfavorable product mix. The company is actively managing these cost pressures through supply chain optimization and targeted pricing actions, aiming to mitigate impacts by fiscal year 2026. Agilent also demonstrated a continued commitment to returning capital to shareholders, with ongoing dividend payments and a substantial share repurchase program. While facing macroeconomic headwinds and increased operating expenses, the company maintains a positive outlook, focusing on innovation and customer experience to drive long-term growth in its key end markets. Liquidity remains strong, supported by robust operating cash flows and existing credit facilities.

Agilent Technologies, Inc. reported net revenue of $1.67 billion for the third quarter of fiscal year 2025, representing a 6% increase year-over-year, with growth driven by its Life Sciences and Diagnostics Markets and Agilent CrossLab segments. For the first six months of fiscal year 2025, net revenue grew 4% to $3.35 billion. Net income for the quarter was $215 million, a decrease from $308 million in the prior year's quarter, impacted by increased restructuring expenses and other costs. The company is navigating a dynamic economic landscape, including inflationary pressures and tariff changes, and is implementing strategies to mitigate these impacts. Despite a decrease in net income for the quarter, driven largely by a significant restructuring charge of $56 million, the company maintained a healthy revenue growth trajectory. Agilent continues to invest in its core segments, particularly Life Sciences and Diagnostics Markets, supported by the BIOVECTRA acquisition. The company is also actively managing its capital structure through share repurchases and dividends, returning value to shareholders while strategically investing in manufacturing capacity expansion.

Agilent Technologies, Inc. reported total net revenue of $1.681 billion for the third fiscal quarter ended January 31, 2025, a slight increase of 1% compared to the prior year period. This growth was driven by the Life Sciences and Diagnostics Markets segment, which saw a 4% increase, and the Agilent CrossLab segment, which grew by 1%. However, the Applied Markets segment experienced a 4% decline in revenue. Net income for the quarter was $318 million, down from $348 million in the same quarter last year, with diluted earnings per share of $1.11 compared to $1.18 in the prior year. Despite a slight revenue increase, the company saw a decrease in overall profitability and a decline in gross and operating margins. The company also repurchased $90 million of its common stock during the quarter and maintained its quarterly dividend, reflecting a continued commitment to returning capital to shareholders. Agilent's cash position remains strong, with cash and cash equivalents totaling $1.467 billion. The company has reorganized its reporting segments, and management anticipates a steady recovery in customer capital budgets while remaining optimistic about long-term market health.

Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and the first nine months of fiscal year 2024 compared to the prior year periods, driven by decreased product sales in its Life Sciences and Applied Markets, and Diagnostics and Genomics segments. This decline was partially offset by revenue growth in the Agilent CrossLab segment. Despite lower revenues, the company saw a significant increase in net income for the quarter, primarily due to strong operational performance and a reduction in costs compared to the prior year, which was impacted by substantial asset impairment charges. Agilent also announced a significant acquisition of BIOVECTRA for $925 million, expected to close before calendar year 2025, signaling a strategic move to expand its capabilities. The company is actively managing its cost structure through restructuring initiatives, including headcount reductions, which contributed to improved operating margins year-over-year. Agilent continues to return capital to shareholders through dividends and a robust share repurchase program, with approximately $709 million remaining authorization under its 2023 repurchase program and a new $2.0 billion program set to begin in August 2024. Despite ongoing market challenges and customer capital expenditure pressures, particularly in China, Agilent remains optimistic about long-term growth prospects in its key end markets.

Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and first six months of fiscal year 2024, down 8% and 7% respectively, compared to the prior year. This decline was primarily driven by the Life Sciences and Applied Markets segment and the Diagnostics and Genomics segment, impacted by customer capital expenditure pressures, particularly in the pharmaceutical market. The Agilent CrossLab segment showed resilience with revenue growth in both periods. Despite the revenue decline, net income remained stable, with $308 million reported for the third quarter and $656 million for the first six months, slightly up from the prior year. Operating cash flow significantly improved, reaching $818 million for the first six months of fiscal year 2024, up from $694 million in the comparable prior-year period. The company also announced a new restructuring plan (FY24 Plan) aimed at further cost reductions, involving approximately 500 employee reductions, with an estimated annual cost savings of $100 million. Additionally, a new $2.0 billion share repurchase program was approved, effective August 1, 2024.

Agilent Technologies, Inc. reported net revenue of $1.658 billion for the third quarter of fiscal year 2024, a decrease of 6% compared to the prior year. This decline was primarily driven by a 9% decrease in product revenue, influenced by customer capital expenditure pressures, particularly in the pharmaceutical and chemical/advanced materials markets. Despite the revenue dip, the company maintained a strong operational performance with net income of $348 million, nearly flat year-over-year. Operating cash flow significantly improved, reaching $485 million compared to $296 million in the prior year. Agilent also continued its commitment to shareholders through dividends and has a substantial remaining authorization for share repurchases. The company is navigating a challenging macroeconomic environment, especially in China, and expects ongoing customer capital expenditure pressures. However, Agilent remains optimistic about its long-term growth prospects across its key end markets, driven by its differentiated product solutions and focus on customer experience and productivity.

Agilent Technologies, Inc. reported total net revenue of $1,672 million for the third quarter of fiscal year 2023, a 3% decrease compared to the prior year. For the first nine months of fiscal year 2023, revenue increased by 3% to $5,145 million. The company experienced a significant decline in income from operations, which was heavily impacted by a substantial asset impairment charge of $277 million related to the shutdown of its Resolution Bioscience business. Despite the revenue dip in the current quarter, driven by weaker demand in the Life Sciences and Applied Markets segment, particularly in Asia Pacific, the company saw growth in its Agilent CrossLab segment. Looking ahead, Agilent anticipates a challenging macroeconomic environment and customer capital expenditure pressures, especially in China, but remains optimistic about long-term growth opportunities across its key markets.

Agilent Technologies, Inc. reported solid financial results for the fiscal second quarter and first half of 2023. Total net revenue increased by 7% and 6% year-over-year for the three and six months ended April 30, 2023, respectively, driven by growth across all segments and geographic regions, although foreign currency movements had an unfavorable impact. Net income also saw a healthy increase, rising to $302 million for the quarter and $654 million for the half-year compared to the prior year periods. The company demonstrated strong operational cash flow generation and maintained a healthy balance sheet. Agilent continues to return capital to shareholders through dividends and share repurchases, with a significant authorization remaining under its new repurchase program. Despite anticipating a challenging macroeconomic environment, Agilent remains optimistic about its long-term growth opportunities.

Agilent Technologies, Inc. reported solid financial results for the third quarter of fiscal year 2023, with total net revenue of $1.756 billion, a 5% increase year-over-year. This growth was achieved despite a 5 percentage point headwind from unfavorable foreign currency movements. The company saw revenue increases across all its segments: Life Sciences and Applied Markets (+6%), Diagnostics and Genomics (+1%), and Agilent CrossLab (+6%). Net income rose to $352 million from $283 million in the prior year period, reflecting improved operational efficiency and strong revenue performance. The company's operational profitability also strengthened, with income from operations increasing by 13% to $426 million and operating margin expanding by 2 percentage points to 24.3%. This was driven by a higher gross margin of 55.1% and disciplined management of operating expenses. Agilent Technologies also demonstrated strong cash generation, with net cash provided by operating activities increasing to $296 million from $255 million in the prior year, indicating robust operational cash flow. The company continues to manage its capital effectively, with ongoing share repurchase programs and consistent dividend payments.

Agilent Technologies, Inc. reported solid revenue growth for the nine months ended July 31, 2022, with total net revenue increasing by 7% year-over-year to $4.999 billion. This growth was primarily driven by a 14% increase in revenue for the three months ended July 31, 2022, despite an unfavorable foreign currency impact of 5 percentage points. The company demonstrated strong performance in the Americas and Asia Pacific regions, with key contributions from the pharmaceutical and chemical and energy end markets. Net income for the nine months increased to $886 million, up from $768 million in the prior year. The company's operating margin improved by 3 percentage points to 22.9% for the nine-month period. Agilent Technologies also continued its commitment to returning capital to shareholders through dividends and a robust share repurchase program, with approximately $573 million remaining authorization under its 2021 repurchase program as of July 31, 2022.

Agilent Technologies, Inc. reported solid financial performance for the three and six months ended April 30, 2022, demonstrating resilience despite global economic headwinds. Total net revenue grew by 5% and 7% year-over-year for the respective periods, reaching $1.61 billion and $3.28 billion. This growth was driven by increases across all business segments, particularly Diagnostics and Genomics, which saw a substantial 14% and 15% revenue increase, respectively. While the company experienced a slight revenue impact from the COVID-19 lockdown in Shanghai, affecting its Gas Chromatography production facility, management anticipates this delayed revenue will be recognized in the latter half of fiscal year 2022 and into fiscal year 2023. Net income also saw a significant improvement, rising to $274 million for the quarter and $557 million for the six-month period, up from $216 million and $504 million in the prior year, respectively. Operationally, the company maintained strong gross margins and improved its operating margin by 4 and 2 percentage points for the three and six-month periods, respectively. Despite increased R&D investments and inflationary pressures on wages, materials, and logistics, Agilent managed its selling, general, and administrative expenses effectively, leading to robust income from operations growth of 25% and 20% year-over-year for the respective periods. The company also continued its commitment to shareholder returns through consistent dividend payments and substantial share repurchases, with $896 million remaining authorization under its 2021 repurchase program as of April 30, 2022. Agilent remains optimistic about its long-term growth prospects across its key end markets, leveraging its diverse portfolio and strategic investments.

Agilent Technologies, Inc. reported strong performance for the third quarter of fiscal year 2022, with total net revenue increasing by 8% year-over-year to $1.674 billion. This growth was broad-based, with increases across all segments, geographies, and key end markets, driven by both product and service revenues. The company demonstrated solid operational execution, with income from operations increasing by 15% year-over-year to $376 million and an operating margin of 22.5%. Despite some unfavorable foreign currency impacts, Agilent's core business remains robust, with particular strength noted in the Diagnostics and Genomics segment which saw a 15% revenue increase. Financially, the company maintained a healthy cash flow from operations of $255 million. Agilent continued its commitment to returning value to shareholders through $63 million in dividends paid and significant share repurchases totaling $447 million during the quarter. While facing ongoing macroeconomic challenges such as supply chain pressures and inflationary costs, Agilent remains optimistic about its long-term growth prospects, supported by new product introductions and strategic investments in its business segments.

Agilent Technologies, Inc. reported a strong third quarter for fiscal year 2021, with total net revenue increasing by 26% year-over-year to $1,586 million. This growth was broad-based, benefiting from increases across all three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company also saw a significant increase in net income, reaching $264 million, up from $199 million in the prior year's quarter. For the first nine months of fiscal year 2021, Agilent demonstrated robust performance with net revenue of $4,659 million, a 21% increase year-over-year. Net income for this period was $768 million, a substantial rise from $497 million in the same period last year. The company also reported a strong operating cash flow of $1,044 million for the nine-month period. Agilent completed a significant acquisition of Resolution Bioscience, Inc., for $550 million plus potential contingent payments, aimed at expanding its capabilities in precision oncology solutions. The company also continued its capital allocation strategy by redeeming its 2022 Senior Notes and issuing new 2031 Senior Notes.

Agilent Technologies, Inc. reported strong financial results for the second quarter and the first half of fiscal year 2021, demonstrating significant year-over-year revenue growth across all segments and geographies. This growth was primarily driven by demand in pharmaceutical, biopharmaceutical, food, and academic markets, with contributions from both product and service revenues. The company also executed strategic financial maneuvers, including the issuance of $850 million in senior notes and the redemption of its 2022 senior notes. Furthermore, Agilent completed a strategic acquisition of Resolution Bioscience, Inc., enhancing its capabilities in precision oncology solutions. Despite ongoing global economic uncertainties, Agilent maintained a robust balance sheet and cash flow from operations, underscoring its financial resilience and commitment to shareholder returns through dividends and share repurchases.

Agilent Technologies, Inc. reported strong financial results for the third quarter of fiscal year 2021, showcasing significant year-over-year growth in both revenue and net income. Total net revenue increased by 14% to $1,548 million, driven by robust performance across all three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Net income also saw a substantial jump to $288 million from $197 million in the prior year's comparable quarter. The company highlighted increased demand for products related to COVID-19 testing and research, alongside a steady recovery in other end markets. Financially, the company demonstrated improved operational efficiency with a 5 percentage point increase in operating margin to 21.2%. Cash flow from operations significantly improved, turning positive at $238 million compared to a use of $59 million in the prior year, partly due to a one-time tax outflow in the previous period. Agilent continued its capital allocation strategy through significant share repurchases totaling $344 million during the quarter, alongside regular dividend payments. Looking ahead, Agilent expressed optimism about continued improvement in financial results despite ongoing uncertainties related to the COVID-19 pandemic.

Agilent Technologies, Inc. reported net revenue of $1,261 million for the third quarter of fiscal year 2020, a slight decrease of 1% compared to the prior year, while nine-month revenue increased 2% to $3,856 million. The company experienced mixed performance across its segments, with Life Sciences and Applied Markets showing a 2% increase in revenue for both periods, while Diagnostics and Genomics saw an 8% decline in the quarter. Agilent CrossLab revenue decreased slightly in the quarter but grew 1% over nine months. Net income for the quarter was $199 million ($0.64 per diluted share), an improvement from $191 million in the prior year, but nine-month net income was significantly impacted by a large tax benefit in the prior year, resulting in $497 million for the current period versus $877 million in the prior year. The company navigated the ongoing COVID-19 pandemic, which affected customer access and demand in certain markets. Despite these challenges, Agilent saw improvements in China and experienced demand for products related to COVID-19 testing and vaccine research. Management highlighted cost-saving measures and maintained a focus on operational efficiency. The company also resumed its share repurchase program in the third quarter after a temporary suspension.

Agilent Technologies, Inc. reported flat total net revenue of $1,238 million for the three months ended April 30, 2020, compared to the same period in the prior year. For the six months ended April 30, 2020, total net revenue increased by 3% to $2,595 million. The company noted that COVID-19 impacted revenue, particularly in the latter part of the second quarter, due to installation delays and laboratory closures. Net income for the three months ended April 30, 2020, decreased to $101 million ($0.32 diluted EPS) from $182 million ($0.57 diluted EPS) in the prior year. The six-month net income also saw a significant decline to $298 million ($0.95 diluted EPS) from $686 million ($2.13 diluted EPS), primarily due to a large discrete tax benefit in the prior year related to a Singapore tax incentive. Despite the challenging environment, Agilent maintained a solid operating margin and continued to manage its capital allocation through dividends and stock repurchases, although repurchases were suspended in March 2020 due to COVID-19.

Agilent Technologies, Inc. reported total net revenue of $1,357 million for the three months ended January 31, 2020, a 6% increase year-over-year. This growth was driven by increases across all three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Despite the revenue growth, net income saw a significant decrease to $197 million from $504 million in the prior year period, largely due to a substantial tax benefit recognized in the prior year. The company experienced a net cash outflow from operating activities of $59 million, primarily impacted by a one-time tax payment of $226 million related to an intellectual property transfer, a notable shift from the $213 million cash inflow in the prior year. Agilent continues to return capital to shareholders through dividends and share repurchases.

Agilent Technologies reported solid top-line growth in the third quarter and first nine months of fiscal year 2019, with total net revenue increasing by 6% and 5% year-over-year, respectively. This growth was driven by strong performance in the Diagnostics and Genomics segment (up 11% and 9%) and Agilent CrossLab (up 10% and 8%), while the Life Sciences and Applied Markets segment showed more modest growth (up 1% and flat). Net income for the quarter was impacted by a significant discrete tax benefit related to Singapore tax incentives, leading to a substantial increase in year-to-date net income compared to the prior year, which was heavily impacted by the U.S. Tax Cuts and Jobs Act. The company also made strategic moves during the period, including entering a new $1 billion credit facility and completing the significant acquisition of BioTek for $1.165 billion shortly after the quarter's end. Agilent continued its commitment to shareholder returns through share repurchases and dividend payments, underscoring a focus on balanced capital allocation. Despite some gross margin pressure due to tariffs and increased wages, the company's operational execution, particularly in services and consumables, alongside strategic acquisitions, positions it for continued growth.

Agilent Technologies, Inc. reported solid revenue growth for the six months ended April 30, 2019, with total net revenue increasing by 4% to $2,522 million compared to the prior year. This growth was driven by strong performance in the Diagnostics and Genomics segment (+9%) and Agilent CrossLab (+8%), while the Life Sciences and Applied Markets segment remained flat. The company's net income for the six months was significantly impacted by a discrete tax benefit of $299 million related to Singapore tax incentives, resulting in a net income of $686 million, a substantial improvement from the net loss of $115 million in the prior year's comparable period which was affected by the U.S. Tax Cuts and Jobs Act. Operationally, Agilent maintained stable gross margins and operating margins, indicating effective cost management. The company also demonstrated a commitment to returning capital to shareholders through $104 million in dividends paid and $125 million in share repurchases during the first six months of the fiscal year. Agilent's strong cash position and newly established $1 billion credit facility provide ample liquidity for ongoing operations and strategic initiatives.

Agilent Technologies, Inc. reported a significant turnaround in its financial performance for the three months ended January 31, 2019, compared to the same period in the prior year. The company swung from a net loss of $320 million to a net income of $504 million. This substantial improvement was primarily driven by a discrete tax benefit of $299 million related to a restructuring and extension of its tax incentive in Singapore, alongside the impact of the U.S. Tax Cuts and Jobs Act in the prior year, which resulted in a large tax charge. Operationally, Agilent saw a 6% increase in total net revenue, reaching $1,284 million, supported by growth across its key segments: Life Sciences and Applied Markets (up 2%), Diagnostics and Genomics (up 13%), and Agilent CrossLab (up 8%). The company also continued its focus on capital allocation, repurchasing $75 million in common stock and paying $52 million in dividends during the quarter. Management expressed optimism for future growth, anticipating contributions from recent acquisitions to offset potential negative impacts from foreign currency movements.

Agilent Technologies, Inc. reported solid revenue growth in the third quarter and first nine months of fiscal year 2018, with total net revenue increasing by 8% and 10% respectively, year-over-year. This growth was driven by strong performance across all three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company also saw an increase in net income for the three-month period, though the nine-month period was significantly impacted by a $533 million discrete tax charge related to the U.S. Tax Cuts and Jobs Act. Strategically, Agilent made several acquisitions during the period, including Lasergen, Genohm SA, Advanced Analytical Technologies, Inc. (AATI), and Ultra Scientific, to expand its capabilities in life sciences and diagnostics. The company continues to focus on product innovation, customer experience, and capital allocation through dividends and share repurchases. Looking ahead, Agilent remains optimistic about growth opportunities and is focused on improving operating margins.

Agilent Technologies, Inc. reported solid revenue growth for the first six months of fiscal year 2018, with total net revenue increasing by 11% year-over-year to $2,417 million. This growth was driven by strong performance across all three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company's profitability for the period was significantly impacted by a one-time discrete tax charge of $533 million related to the U.S. Tax Cuts and Jobs Act, resulting in a net loss of $115 million for the six months, compared to a net income of $332 million in the prior year. Excluding this tax impact, the company demonstrated operational strength and continued its focus on strategic acquisitions, with several key deals completed or announced in May 2018 to expand its market offerings. Operationally, Agilent saw an increase in net income for the third quarter of fiscal 2018 to $205 million, up from $164 million in the same period last year, with diluted earnings per share at $0.63. The company continues to generate strong operating cash flow, amounting to $518 million for the first six months of fiscal 2018. Agilent also remains committed to returning capital to shareholders through dividends and share repurchases, with $96 million in dividends paid and $93 million in share repurchases during the six-month period. The company's balance sheet remains robust with $3,011 million in cash and cash equivalents as of April 30, 2018.

Agilent Technologies reported strong top-line growth for the three months ended January 31, 2018, with total net revenue increasing by 14% year-over-year to $1.21 billion. This growth was driven by solid performance across all three segments: Life Sciences and Applied Markets (+14%), Diagnostics and Genomics (+13%), and Agilent CrossLab (+12%). The company's profitability, however, was significantly impacted by a one-time discrete tax charge of $533 million related to the enactment of the U.S. Tax Cuts and Jobs Act, resulting in a net loss of $320 million for the quarter, a stark contrast to the net income of $168 million reported in the prior year. Despite the net loss, operating cash flow showed a substantial improvement, increasing to $215 million from $116 million in the same period last year, indicating strong underlying operational cash generation.

Agilent Technologies, Inc. reported solid financial performance for the nine months ended July 31, 2017, demonstrating revenue growth across its key business segments and an improvement in profitability. Total net revenue increased by 6% year-over-year to $3.3 billion, driven by a 5% increase in Life Sciences and Applied Markets, a 9% increase in Diagnostics and Genomics, and a 7% increase in Agilent CrossLab. Net income saw a significant rise to $507 million, up from $336 million in the prior year period, reflecting improved gross margins and operational efficiencies. The company's balance sheet remains strong, with cash and cash equivalents totaling $2.56 billion as of July 31, 2017. Agilent continues to focus on returning value to shareholders through dividends and share repurchases, while also investing in research and development to fuel future growth. The company made strategic acquisitions of Multiplicom NV and Cobalt Light Systems, which are expected to contribute to its diagnostics and applied markets businesses.

Agilent Technologies, Inc. reported a strong second quarter for fiscal year 2017, with total net revenue increasing by 8% year-over-year to $1.102 billion. This growth was driven by solid performance across all three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Net income saw a significant increase, reaching $164 million ($0.50 per diluted share) compared to $91 million ($0.28 per diluted share) in the prior year's second quarter. The company generated $373 million in cash from operations for the first six months of fiscal 2017, demonstrating robust cash flow. Agilent continues to focus on strategic growth initiatives and returning value to shareholders through dividends and share repurchases. Management expressed optimism for continued growth, particularly in the pharmaceutical and biotechnology, and diagnostics and clinical markets.

Agilent Technologies, Inc. reported a solid performance for the three months ended January 31, 2017, with total net revenue increasing by 4% year-over-year to $1,067 million. This growth was driven by a 3% increase in Products revenue and a 7% increase in Services and other revenue. Net income rose significantly to $168 million, up from $121 million in the prior year period, leading to diluted EPS of $0.52. The company successfully managed its expenses, with selling, general, and administrative costs decreasing by 5%, contributing to a notable expansion in operating margin by 4 percentage points to 19.3%. Key drivers of performance included growth across all three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, with revenue increases of 3%, 4%, and 6%, respectively. The company also completed the acquisition of Multiplicom NV for approximately $72 million, strengthening its Diagnostics and Genomics segment. Agilent continues to prioritize shareholder returns, repurchasing $111 million in shares during the quarter and paying a dividend of $0.132 per share. The company maintains a strong liquidity position with $2,241 million in cash and cash equivalents.

Agilent Technologies, Inc. reported solid performance for the nine months ended July 31, 2016, with total net revenue increasing by 3% to $3,091 million compared to the prior year. This growth was driven by strong performance in the Diagnostics and Genomics segment (+7%) and Agilent CrossLab (+6%), while the Life Sciences and Applied Markets segment remained flat. Net income from continuing operations rose to $336 million from $298 million in the same period last year. The company also generated significant cash flow from operations ($559 million), underscoring its financial health. Agilent continued its commitment to shareholder returns through dividends and share repurchases, with $112 million in dividends paid and $290 million in shares repurchased during the nine-month period. Recent acquisitions, including Seahorse Bioscience and iLab Solutions, are expected to contribute to future growth. Financially, Agilent maintained a strong balance sheet with $2,199 million in cash and cash equivalents as of July 31, 2016. The company also made progress on operational efficiencies and strategic initiatives, including a focus on improving operating margins. While facing some currency headwinds, Agilent demonstrated resilience and strategic execution, positioning itself for continued growth in its key markets.

Agilent Technologies, Inc. reported solid revenue growth for the three and six months ended April 30, 2016, with total net revenue increasing by 6% and 3% respectively, year-over-year. This growth was driven by strong performance across its business segments, particularly Agilent CrossLab and Diagnostics and Genomics, with Life Sciences and Applied Markets showing moderate improvement. The company demonstrated improved profitability, with gross margins increasing by 2 percentage points and operating margins by 2 and 3 percentage points for the three and six-month periods, respectively. This margin expansion was attributed to factors like exiting the NMR business, improved logistics, and a pension curtailment gain. Financially, Agilent maintained a strong liquidity position with $2,139 million in cash and cash equivalents. The company continued to return capital to shareholders through dividends and share repurchases, demonstrating confidence in its ongoing cash flow generation. Significant investments were made in acquisitions, including Seahorse Bioscience, and strategic equity investments, such as Lasergen, indicating a focus on future growth and innovation. Despite some unfavorable foreign currency impacts, the company expressed optimism for continued growth, focusing on operating margin expansion and strategic investments.

Agilent Technologies, Inc. reported a net revenue of $1.028 billion for the three months ended January 31, 2016, which was flat compared to the prior year period. Despite a 2% revenue decline in Products, Services and other revenue increased by 7% to $233 million. The company saw mixed segment performance, with Life Sciences and Applied Markets revenue down 4% and Diagnostics and Genomics up 7%, while Agilent CrossLab grew 4%. Net income from continuing operations significantly increased by 32% to $123 million, translating to diluted EPS of $0.37, up from $0.19 in the prior year. This improvement was driven by higher gross and operating margins, aided by cost controls and a pension curtailment gain, along with reduced R&D expenses. Financially, Agilent maintained a strong liquidity position with $1.931 billion in cash and cash equivalents. The company generated $104 million in cash from operations, a substantial improvement from the $20 million used in the prior year. Agilent continued its capital return strategy by repurchasing $200 million of its stock and paying $38 million in dividends during the quarter. The acquisition of Seahorse Bioscience for $242 million was completed, adding to the company's strategic investments and goodwill.

Agilent Technologies, Inc. reported steady performance for the third quarter and first nine months of fiscal year 2015, with net revenue reaching $1,014 million and $3,003 million respectively. While overall revenue was largely flat year-over-year, the company navigated challenges from foreign currency headwinds which unfavorably impacted revenue by approximately 6-7 percentage points. The separation of Keysight Technologies, Inc. in late 2014 has been completed, and its results are now reported under discontinued operations. Agilent has also reorganized into three new reporting segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company announced an agreement to acquire Cartagenia for €60 million, bolstering its capabilities in clinical genetics and molecular pathology. Management is focused on organic growth and expanding operating margins, with plans to return significant cash flow to shareholders through dividends and share repurchases. The company's liquidity position remains strong, with substantial cash and cash equivalents, and confidence in its ability to meet its financial obligations.

Agilent Technologies, Inc. reported its fiscal second-quarter 2015 results, with total net revenue of $963 million, a slight decrease of 3% year-over-year, impacted by unfavorable foreign currency movements. Net income was $83 million ($0.25 per diluted share). The company continues to navigate the post-Keysight separation landscape, with Keysight's historical results now reported as discontinued operations. Agilent has also realigned its business segments into Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. While overall revenue saw a modest decline, the company highlighted efforts to drive organic growth through innovation and expanded services. Management expressed confidence in future growth opportunities, particularly in the Life Sciences and Applied Markets and Diagnostics and Genomics segments, driven by demand in pharmaceutical and biotechnology sectors. The company also announced a new $1.14 billion share repurchase program, underscoring a commitment to shareholder returns.

Agilent Technologies, Inc. reported financial results for the first quarter ended January 31, 2015, which were significantly impacted by the separation of its electronic measurement business, Keysight Technologies, Inc., completed on November 1, 2014. This separation led to Keysight's results being classified as discontinued operations. For the quarter, Agilent saw a modest 2% increase in total net revenue to $1,026 million, compared to $1,008 million in the prior year. However, net income from continuing operations decreased to $102 million ($0.30 per diluted share) from $121 million ($0.36 per diluted share) in the prior year. This decrease was partly due to separation-related expenses and transformational charges. The company also noted an unfavorable impact from foreign currency movements. The company has reorganized into three new reportable segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. While Life Sciences and Applied Markets revenue grew 2%, Diagnostics and Genomics revenue declined 6% due to manufacturing issues. Agilent CrossLab showed a 5% revenue increase. Investors should note the ongoing impact of currency fluctuations and the successful completion of the Keysight separation as key themes for the period.

Agilent Technologies, Inc. reported its results for the third quarter and the first nine months of fiscal year 2014. For the three months ended July 31, 2014, net revenue increased by 7% to $1.766 billion compared to the prior year. Net income for the quarter was $147 million, a decrease from $168 million in the same period last year, resulting in diluted earnings per share of $0.43. For the nine months ended July 31, 2014, net revenue grew 2% to $5.176 billion, while net income decreased to $481 million from $513 million in the prior year, with diluted earnings per share of $1.42. A significant event impacting the company is the planned separation of its electronic measurement business into a new entity named Keysight Technologies, Inc. This separation was expected to be completed in early November 2014. The company incurred pre-separation expenses of $123 million in the first nine months of fiscal 2014 related to this transaction. Agilent's core businesses are now focused on life sciences, diagnostics, and chemical analysis.

Agilent Technologies, Inc. reported flat total net revenue of $1.73 billion for the third quarter of fiscal year 2014, consistent with the prior year's period. Net income for the quarter was $139 million, a decrease from $166 million in the same period last year. The company is actively managing its portfolio, including the planned separation of its electronic measurement business into Keysight Technologies, expected in early November 2014, and has initiated restructuring programs. Despite stable overall revenue, performance varied across segments, with growth in Life Sciences and Diagnostics and Chemical Analysis offset by a decline in Electronic Measurement. The company generated $519 million in operating cash flow for the first six months of fiscal year 2014.

Agilent Technologies, Inc. reported relatively flat net revenue of $1.679 billion for the three months ended January 31, 2014, compared to $1.680 billion in the prior year's comparable period. Despite this, net income saw an increase to $195 million from $179 million year-over-year, driven by a significant discrete tax benefit related to an IRS audit settlement. The company is actively engaged in a strategic separation of its electronic measurement business into a new entity, Keysight Technologies, Inc., expected to be completed by November 2014. Operational performance varied across segments. The Life Sciences and Diagnostics business showed revenue growth of 5%, while the Chemical Analysis segment grew by 6%. Conversely, the Electronic Measurement segment experienced a 7% decline in revenue, largely due to weakness in aerospace and defense markets. The company continues to invest in Research and Development, maintaining its commitment to approximately 10% of revenues, with a focus on strategic opportunities. Agilent also repurchased $100 million of its stock during the quarter and paid $44 million in dividends, reflecting a commitment to returning value to shareholders.

Agilent Technologies, Inc. reported a 4% decrease in net revenue to $1.65 billion for the third quarter of fiscal year 2013, compared to the same period last year. This decline was primarily driven by a significant 17% decrease in the Electronic Measurement segment, attributed to weak market conditions and the loss of a large customer. However, the Diagnostics and Genomics segment saw substantial growth, up 54%, largely due to the acquisition of Dako A/S. Net income for the quarter was $168 million, a decrease from $243 million in the prior year, impacted by factors including restructuring charges. The company continues to face macroeconomic challenges, particularly in the Electronic Measurement segment. Despite the overall revenue decline, Agilent maintained a stable gross margin and demonstrated operational resilience in its Life Sciences and Chemical Analysis segments, which experienced modest revenue growth. The company also generated $775 million in operating cash flow for the nine months ended July 31, 2013, indicating strong cash generation capabilities despite revenue headwinds.

Agilent Technologies, Inc. reported flat total net revenue of $1.732 billion for the three months ended April 30, 2013, compared to the prior year, and a 1% increase to $3.412 billion for the six months ended April 30, 2013. While overall revenue remained stable, the company experienced significant shifts across its business segments. The Diagnostics and Genomics segment saw substantial growth, largely driven by the acquisition of Dako A/S. Conversely, the Electronic Measurement segment experienced a notable decline in both orders and revenue. Net income for the three and six-month periods decreased year-over-year to $166 million and $345 million, respectively, impacting diluted earnings per share. The company generated $560 million in operating cash flow for the six months ended April 30, 2013, an increase from the prior year. Agilent also continued its capital return strategy, paying dividends and actively repurchasing shares under its enhanced share repurchase program. The company initiated a restructuring program aimed at reducing headcount and associated costs, anticipating a significant annual expense reduction.

Agilent Technologies, Inc. reported a net revenue of $1,680 million for the three months ended January 31, 2013, a 3% increase compared to the prior year. This growth was significantly driven by the acquisition of Dako A/S, which contributed 6 percentage points to revenue growth. While overall revenue increased, net income decreased to $179 million from $230 million in the comparable prior period, impacted by increased operating expenses related to the Dako acquisition and other factors. The company generated $245 million in cash from operations, a notable improvement from $150 million in the prior year. The company's segment performance showed mixed results. The Diagnostics and Genomics segment experienced substantial growth of 145%, largely due to the Dako acquisition. Conversely, the Electronic Measurement segment saw a 7% revenue decrease, and Chemical Analysis revenue declined by 1%. Life Sciences revenue grew by 2%. Agilent continues to navigate a slow-growth economic environment, with management focused on product innovation and operational optimization to achieve cost savings.

Agilent Technologies, Inc. reported its financial results for the third quarter of fiscal year 2012, ending July 31, 2012. The company demonstrated solid revenue growth, primarily driven by its life sciences and diagnostics segments. This top-line expansion, coupled with effective cost management, led to an increase in profitability and earnings per share compared to the prior year period. Investors should note the continued strength in recurring revenue streams which provide a stable base for future performance. The company's strategic focus on innovation and market expansion in key growth areas appears to be yielding positive results. While the overall performance was robust, it's important for investors to consider the broader economic environment and potential currency headwinds mentioned in the report. Agilent's management expressed confidence in its ongoing strategies and its ability to navigate challenges, reiterating its full-year guidance. The company's investment in research and development and its commitment to operational efficiency are key factors supporting its long-term growth prospects. Investors seeking exposure to the analytical instruments and life sciences sectors will find Agilent's performance in this quarter to be a positive indicator of its market position and execution capabilities.

Agilent Technologies, Inc. reported its financial results for the nine months ended July 31, 2012. The company experienced a modest increase in total net revenue, up 4% year-over-year to $5,091 million. This growth was primarily driven by the strategic acquisition of Dako A/S, which significantly boosted the Diagnostics and Genomics segment. While overall revenue saw growth, the company noted a challenging economic environment impacting some segments like Chemical Analysis and Electronic Measurement, which experienced slight revenue declines or flat performance. Net income for the nine-month period was $728 million, slightly up from $723 million in the prior year. The company generated $743 million in cash from operating activities, demonstrating solid operational cash flow. Agilent continued its focus on innovation and market leadership while navigating economic uncertainties. The company also initiated a quarterly cash dividend, returning value to shareholders.

Agilent Technologies reported solid financial results for the quarter ended April 30, 2012, with total net revenue increasing by 3% to $1.733 billion and net income rising to $255 million, up from $200 million in the prior year period. This growth was driven by strong performance across its key segments, particularly in Chemical Analysis and Electronic Measurement, despite a slight dip in Life Sciences orders. The company also announced a significant strategic move with the proposed acquisition of Dako A/S for approximately $2.2 billion, to be funded by existing cash reserves, signaling a commitment to expanding its diagnostics and pathology offerings. Operationally, Agilent demonstrated disciplined expense management, with selling, general, and administrative expenses decreasing year-over-year. The company generated $503 million in cash from operating activities for the six-month period, underscoring its strong cash-generation capabilities. Agilent also initiated a quarterly cash dividend, returning capital to shareholders. Looking ahead, the company expressed confidence in navigating economic uncertainties and leveraging growth opportunities, particularly in emerging markets.

Agilent Technologies, Inc. reported strong revenue growth for the three months ended January 31, 2012, with total net revenue increasing by 8% year-over-year to $1.635 billion. This growth was driven primarily by robust performance in the Life Sciences and Chemical Analysis segments. Net income also saw a significant increase, rising to $230 million from $193 million in the prior year period, reflecting improved operational efficiency and revenue growth. The company generated $150 million in cash from operations, demonstrating solid cash flow generation. Key strategic developments include the declaration of Agilent's first quarterly dividend of $0.10 per share, signaling a commitment to returning value to shareholders. The company continues to focus on integrating the Varian acquisition, expecting to achieve $100 million in net cost savings, with a significant portion already realized. Looking ahead, Agilent remains focused on delivering market-leading products, optimizing operations, and leveraging opportunities in emerging markets and through strategic acquisitions to drive future growth.

Agilent Technologies, Inc. reported strong revenue growth for the third quarter and first nine months ended July 31, 2011, driven by its Life Sciences, Chemical Analysis, and Electronic Measurement segments. Total net revenue increased by 22% and 26% year-over-year for the respective periods, largely supported by the acquisition of Varian, Inc. Net income saw a significant rise, more than doubling for the nine-month period, reflecting improved operational performance and the impact of the Varian integration. The company generated substantial operating cash flow, demonstrating solid financial health and liquidity.

Agilent Technologies, Inc. reported strong financial performance for the quarter and six months ended April 30, 2011, with significant year-over-year increases in orders, net revenue, and net income. Total net revenue grew 32% and 29% for the three and six-month periods, respectively, driven by robust performance across all business segments: Life Sciences, Chemical Analysis, and Electronic Measurement. This growth was bolstered by recent acquisitions, notably Varian, Inc., which contributed significantly to revenue and order expansion. The company also successfully integrated three smaller businesses, further diversifying its portfolio. Profitability saw a substantial improvement, with net income more than doubling in the six-month period. Cash flow from operations also demonstrated strong growth, indicating healthy operational efficiency. Agilent continues to focus on integrating its recent acquisitions, realizing cost and revenue synergies, and investing in research and development to maintain its competitive edge in the measurement solutions market. The company appears well-positioned for continued growth, supported by strong demand in key end-markets such as pharmaceutical, biotechnology, and petrochemical sectors.

Agilent Technologies, Inc. reported strong financial performance for the quarter ended January 31, 2011, with net revenue increasing by 25% year-over-year to $1.519 billion. This growth was driven by a significant increase in orders across all business segments, particularly in Life Sciences and Chemical Analysis, partly due to the integration of the Varian, Inc. acquisition. Net income also saw a substantial rise, reaching $193 million compared to $79 million in the prior year's comparable period, indicating improved profitability and effective cost management. The company's operational efficiency improved, with operating margins increasing to 13.9% from 7.8% year-over-year. Cash flow from operations was robust at $120 million, demonstrating the company's ability to generate cash from its core business. Agilent continues to focus on integrating the Varian acquisition, expecting to achieve significant cost savings and revenue synergies. The company also highlighted its ongoing commitment to research and development, aiming to maintain approximately 10% of revenues, and its strategic manufacturing capacity expansion for its electronic measurement business.

This filing is an amendment (10-Q/A) to Agilent Technologies, Inc.'s Quarterly Report on Form 10-Q for the quarter ended July 31, 2010. The amendment's sole purpose is to furnish Interactive Data (XBRL) as required by SEC regulations. Crucially, this amendment does not update or alter any financial or operational information originally disclosed in the September 7, 2010, filing. Investors should refer to the original Form 10-Q for the company's financial performance and operational details for the quarter.

Agilent Technologies, Inc. reported strong financial performance for the quarter ended July 31, 2010, driven by significant revenue growth and a substantial increase in net income compared to the prior year. This improvement was largely fueled by the recent acquisition of Varian, Inc., which significantly boosted orders and revenue across the Life Sciences and Chemical Analysis segments. The company also saw a recovery in its Electronic Measurement segment, with increased orders and revenue. Despite the positive top-line growth and profitability, investors should note the substantial increase in goodwill and intangible assets on the balance sheet due to the Varian acquisition, as well as the associated integration efforts and potential synergies that management is focused on realizing. Financially, Agilent demonstrated improved operational efficiency, evidenced by higher gross and operating margins. Cash flow from operations also saw a significant increase year-over-year. The company has strategically managed its debt, issuing new senior notes and utilizing existing cash to fund the Varian acquisition and repay outstanding debt. While the Varian acquisition presents growth opportunities, it also introduces integration challenges and requires careful monitoring of related expenses and synergies. Investors should keep an eye on the company's ability to successfully integrate Varian and achieve expected synergies, as well as the ongoing competitive landscape and global economic uncertainties.